Title: Diagnosis, management and attitudes about idiopathic pulmonary fibrosis among Turkish pulmonologists
|
|
- Drusilla Whitehead
- 5 years ago
- Views:
Transcription
1 1 Manuscript type: Original Article DOI: /TurkThoracJ Title: Diagnosis, management and attitudes about idiopathic pulmonary fibrosis among Turkish pulmonologists Short title: Idiopathic pulmonary fibrosis survey-turkey Authors: Haluk Türktaş 1, Gülfer Okumuş 2, Oğuz Uzun 3, Özlem Özdemir Kumbasar 4, Göksel Altınışık 5, Züleyha Bingöl 2, Şermin Börekçi 6, Vincent Cottin 7, Benan Müsellim 6 Instutions: 1 Department of Pulmonary Diseases, Gazi University, School of Medicine, Ankara, Turkey 2 Department of Pulmonary Diseases, İstanbul University, İstanbul School of Medicine, Istanbul, Turkey 3 Department of Pulmonary Diseases, Ondokuz Mayıs University, School of Medicine, Samsun, Turkey 4 Department of Pulmonary Diseases, Ankara University, School of Medicine, Ankara, Turkey 5 Department of Pulmonary Diseases, Pamukkale University, School of Medicine, Denizli, Turkey 6 Department of Pulmonary Diseases, İstanbul University-Cerrahpaşa, Cerrahpaşa School of Medicine, İstanbul, Turkey 7 Claude Bernard University, Reference Center for Rare Pulmonary Diseases, UMR754, Lyon, France Address for correspondence: Haluk Türktaş, Department of Pulmonary Diseases, Gazi University, School of Medicine, Ankara, Turkey halukturktas@gmail.com Received: Accepted: Cite this article as: Türktaş H, Okumuş G, Uzun O, et al. Diagnosis, management and attitudes about idiopathic pulmonary fibrosis among Turkish pulmonologists. Turk Thorac J 2019; DOI: /TurkThoracJ
2 2 ABSTRACT Objective: The aim of this study is to determine the approaches of Turkish pulmonologists to the diagnosis and treatment of patients with idiopathic pulmonary fibrosis (IPF) in daily clinical practice. Material and methods: A questionnaire containing 38 questions about IPF diagnosis and treatment was applied to pulmonologists between January 2018 and data of 158 physicians who responded to the questionnaire were evaluated. Results: Results of this survey showed that mean number of patients that physicians follow-up and managed annually was 8.3 and 5 respectively. The mean symptom duration of the patients before the diagnosis was 9-12 months. Patients have been seen by average three physicians prior to confirmed diagnosis. Almost 80% of the physicians have opportunity to access a pathologist and radiologist who are specialized in IPF. However only 26% of them have opportunity to access regular multidisciplinary meetings. Although the most commonly prescribed drugs were antifibrotics, approximately 10% of patients were prescribed steroids, N-acetylcysteine and immunosuppressive drugs. Most of the physicians (81%) were aware of international guidelines however Turkish Thoracic Society Idiopathic Pulmonary Fibrosis Diagnosis and Treatment Consensus Report was read by only 41% of them. Conclusion: This survey may lead to IPF awareness in Turkey, and may help closing the gaps on diagnosis and treatment. KEYWORDS: idiopathic pulmonary fibrosis; survey; Turkey
3 3 INTRODUCTION Idiopathic Pulmonary Fibrosis (IPF) is a chronic, progressive disease of the lungs with irreversible fibrosis. The pathogenetic mechanisms are not fully explained [1, 2]. There is rapid loss of respiratory function and unpredictable prognosis. The average life expectancy of the patients is 3-5 years. There are serious problems in diagnosis and treatment of IPF. IPF is an orphan disease with an estimated incidence in United States is between 6.8 and 8.8/ [3, 4], in United Kingdom 2.85/ [5]. In Turkey there is no data about incidence and prevalence of IPF but estimated incidence of all interstitial lung diseases is 25.8/ [6]. In 2011, an international consensus report (by ATS / ERS / JTS / ALAT) and in 2018 a national consensus report by the Turkish Thoracic Society were published to standardize the diagnosis and treatment of IPF [7, 8]. According to these guidelines, high resolution computed tomography (HRCT) plays key role in the diagnosis of IPF. In HRCT, the diagnosis of IPF is made by the existence of usual interstitial pneumonia (UIP) pattern and after exclusion of known causes of interstitial lung disease. Surgical lung biopsy is recommended in patients with possible UIP pattern in HRCT. It is emphasized that multidisciplinary council meetings where clinical, radiological and pathological findings are discussed together are very important in the diagnosis of IPF. Studies about the treatment of IPF have shown that steroids, N-acetylcysteine, anticoagulant and immunosuppressive drugs have no place in treatment. Currently antifibrotic drugs such as pirfenidone and nintedanib are recommended for the treatment of IPF [7, 9, 10]. MATERIALS AND METHODS This study was planned and performed by the Turkish Thoracic Society Clinical Problems Study Group. This is a survey study performed on physicians. All of the physicians voluntarily gave their informed concent and answered the questionnaire sent by . The study was carried out according to the principles of the Declaration of Helsinki. Advancing IPF Research (AIR) Survey questionnaire used in European countries has been applied. The AIR Survey questionnaire consisted of 28 questions [11]. We added several questions to assess the approaches and attitudes of
4 4 pulmonologist about IPF. The questionnaire consists of 38 questions relating to the diagnosis and treatment of IPF. The questions were about the approaches of physicians in daily clinical practice for the diagnosis and treatment of IPF. The questionnaire was sent by to the chest physicians who are listed in Turkish Thoracic Society database. Physicians were given a week between 22 th and 29 th of January 2018 to complete the questionnaire. The responses of the physicians who completed the questionnaire were analyzed. RESULTS Characteristics of respondents At the end of the determined period, 247 physicians completed the questionnaire. The responses of 158 pulmonologists who followed at least one IPF patient are evaluated. More than half of the physicians participating in the survey were women (n=87, 55%) and 71 (45%) were men and 112 (%71) of them were older than 40 years of age. Most of the physicians were working in academic centers (n=124, 80%) and 34 physicians (20%) were working in non-academic hospitals. The survey responses showed that the total number of IPF patients followed by respondents were about 940. The number of patients followed by each physician ranged from 2 to 200 (mean 8.3). Total number of patients who received treatment in the last year was 530, ranged 1 to 50 per physician. The average number of IPF patients treated by a physician per year is 5 (Table 1). Diagnosis of IPF Approximately two thirds of the survey respondents had access to a radiologist (71%) and a pathologist (67%) at their institution, but one third did not have this opportunity (Figure 1). Multidisciplinary team (MDT) discussion including pulmonologist, radiologist and pathologist is crucial for the diagnosis of IPF. However, 26% of the respondents have regular MDT meetings, 36% have irregular and 38% have no MDT meeting (Figure 2). The average symptom duration was 9-12 months before the diagnosis and patients were seen by average 3 physicians before the confirmed diagnosis of IPF. One third of the patients had been seen by four or more physicians (Figure 3).
5 5 At the diagnosis of IPF almost all the physicians explored the occupational risk factors and 82% of them asked whether there is a family history of fibrotic interstitial lung disease or not. Genetic tests were performed by 20% of the physicians if there is a family history. Only 15% of the physicians always perform bronchoalveolar lavage (BAL) examination in the diagnosis of IPF and 85% of them perform in only selected patients such as younger, non-smoker patients, patients with pre-diagnosis of hypersensitivity pneumonia and patients with possible UİP pattern in HRCT. The ratio of physicians who always recommend surgical lung biopsy for the diagnosis of IPF is 22%. Surgical biopsy is usually recommended in younger patients. ATS / ERS / JRS / ALAT IPF guidelines were considered useful by 81% of physicians, while 16% stated that they did not read the guideline in detail. Only 41% of the physicians read the Turkish Thoracic Society IPF Consensus Report, 46% of them were aware of the report but they have not read yet and 13% have not heard about it. IPF Treatment IPF treatment decision was made on their own by 27%, discussing with other pulmonologist by 31% and multidisciplinary team discussion by27% of respondents. The most commonly initiated treatments are pirfenidone and nintedanib. Corticosteroids, NAC, immunosuppressive drugs are used alone or in combination in 10-15% of the patients (Figure 4). For patients with the diagnosis of definite IPF; 68% of the physicians started the antifibrotic drugs early, 27% of them followed the progression of the disease for at least 3 months and decided to treat according to the progression of the disease. For the patients with the diagnosis of possible IPF, 18% of the physicians started treatment early, 67% followed the patients for at least 3 months and they started treatment according to the progression of the disease (Figure 5).
6 6 Approximately 80% of physicians assess the progression of the disease by FVC, DLCO and 6 minutes walking test. Lung transplantation was performed to 17 of the patients who were followed-up by the physicians in this survey. When IPF treatment is considered, 75% of physicians give priority to early diagnosis, 70% to effectiveness of treatment and monitoring of side effects, 61% to follow-up plan, 59% to reach a definitive diagnosis and 57% to treatment of comorbidities. Comorbidities Comorbidities are very common in IPF patients. The most common comorbidities were pulmonary hypertension, gastroesophageal reflux (GER), emphysema, cardiovascular diseases and lung cancer (Figure 6). In patients diagnosed with IPF, 83% of the physicians always investigate the symptoms of GER.26% of the respondents routinely treat GER whether the patients have GER symptoms or not, but 73% only treat patients with symptomatic or documented GER. In patients with pulmonary hypertension, 11% of the physicians regularly treat pulmonary hypertension in patients with IPF, 41% treat occasionally and 48% never give any specific treatment for pulmonary hypertension. DISCUSSION This is the first survey to assess the attitudes and current approaches of Turkish pulmonologists about the diagnosis and management of IPF. With this survey we had the opportunity of comparing our results with other international surveys. Seventy nine percent of respondents were working in university hospitals or in education hospitals of the ministry of health. Because of the difficulties in diagnosis and management of IPF, majority of the patients were followed by tertiary care settings and this may explain the higher rate of respondents from academic centers.
7 7 The mean number of patients treated annually by each physician was five. Forty one percent of physicians report that they treat less than 5 patients per year and 51% of them treat between 5-20 patients. Similarly in Polish survey with 150 participitants; 52% of the physicians managed less than 5 IPF patients per year and 9% of them manage more than 20 patients [12]. In Latin American survey the average number of IPF patients managed previous year was 13.8 [13]. In French survey the mean number of patients managed annually was 56 [14] and in European survey it was 39 [11]. The reason for this higher number of patients in France and Europe may be explained by that majority of the respondents in French and European survey was from IPF centers. In order to reveal the awareness of participitants about the national and international guidelines, our survey had several questions about the guidelines. Most of the respondents (81%) declared that they read the ATS/ERS/JRS/ ALAT IPF guidelines and considered it useful for the management of IPF. In contrast only 41% read, and another 46% was aware of but did not read the Turkish Thoracic Society IPF Consensus Report and 13% did not hear about the report. In our opinion, the reason for this was that the survey was done just a few months after the publication of the national consensus report so there was a very short period of time between the publication of national consensus report and the survey. We believe that future studies will reflect the actual usage of the national report more accurately. At diagnosis 96% of physicians explore lung fibrosis in families of IPF patients, and perform genetic tests for %20 of those patients who have family history of fibrotic interstitial lung disease. In the European survey the rate of questioning of fibrotic disease in the family is 94% and 29% of them performing genetic tests [11]. This rate is 77% in French study [14]. Although there is no recommendation for genetic study in ATS / ERS / JRS / ALAT IPF guidelines, such high rates of genetic testing is surprising [15]. A patient who presented with symptoms compatible with IPF has a period of approximately one year before the confirmed diagnosis of IPF and every patient is seen by 3 physicians before the diagnosis. Similarly in the IPF survey conducted in Europe, it is stated that there is an average delay of one year for the diagnosis and the patients seen by two or more physicians prior to the diagnosis of IPF.
8 8 In Turkey approximately 71% of the respondents have opportunity to access a radiologist and 67% to a pathologist in their institution. Access to radiologist and pathologist in Latin America is 39% and 28%, in France 63% and 66% and in Europe 85% and 74% respectively [11, 13, 14]. Although the higher availability and easy accessibility to radiologist and pathologist in our country we have two main problems in the diagnosis of IPF. First we have few numbers of experienced radiologist and pathologist in IPF, and the second is the inability in gathering a MDT. This survey results show us that only 26% of participating institutions have regular multidisciplinary meeting discussion. Nearly one third (36%) have irregular meetings and 38% have no MDT meeting in their hospitals. In French and European surveys the vast majority of IPF cases were diagnosed by multidisciplinary discussion. Only 7% of European responders and 3% of French pulmonologists reported that the diagnosis of IPF was made without multidisciplinary discussion [11, 14]. In Latin American survey access to multidisciplinary team was 41.1% among pulmonologist [13]. In Turkey IPF treatment decision was made alone by 27% of the physicians, 31% by consulting with other chest diseases specialists, and 27% by the multidisciplinary discussion. The rate of physicians who stated that they gave treatment decisions alone in Europe was 7% and in Latin America it was 20%. Treatment decision should be given by multidisciplinary council discussions, but the rate of making decision alone by a physician is quite high. The most common initiated drugs for the treatment of IPF are antifibrotics. Most of the Turkish physicians (78%) reported that they prescribe pirfenidone as an antifibrotic and 50% nintedanib. The prescription rate of antifibrotic drugs was 81% in Europe, 60% in Latin America and 11% in Poland [11-13]. The low rate of prescription in Poland can be explained by the late reimbursement of these drugs for IPF. Corticosteroid therapy in monotherapy or in different combinations was recommended by 37% of respondents. Very similarly, 43%, 57% and 83% of the physicians from Poland, Europe and Latin America respectively prescribe corticosteroids alone or with combinations for treatment of IPF [11-13]. As mentioned in European survey report the possible reasons for prescription of nonantifibrotic drugs may be that in clinical practice such therapies demonstrate a benefit in some patients with conditions similar to IPF, or that the patients themselves may be reluctant to stop
9 9 certain medications. Fifteen percent of responders tried immunosuppressive therapies before starting antifibrotic drugs in patients with possible IPF. Early initiation of antifibrotic drug for treatment of IPF is recommended [16]. From the point of view of initiation time of antifibrotic drugs, 68% of physicians start treatment upon diagnosis irrespective of symptoms in patients with the diagnosis of definite IPF and 27% of the responders follow the patient at least 3 months to evaluate the progression of the disease and started treatment if progression occurs. In patients with the diagnosis of possible IPF, 18% of physicians initiate treatment early, 67% started after 3 months follow-up. The most common reported comorbidities in patients with IPF are emphysema, GER, cardiovascular diseases and pulmonary hypertension. Most of physicians (83%) always ask the patient if they have GER symptoms. Twenty six percent of the physicians routinely treat GER irrespective of symptoms, but 73% of them treat only patients with symptoms. Regarding to pulmonary hypertension; 11% of the physicians regularly treat pulmonary hypertension. In European survey, this rate is 4% and in Latin America it is 50% [11, 13]. Although there is no recommendation for the treatment of pulmonary hypertension in the guidelines, it is also interesting that the rates of treatment are as high as 50% and there are significant differences between countries. In summary, the results of this survey provide a snapshot showing the approaches of Turkish pulmonologists for the diagnosis and treatment of IPF in daily clinical practice. Majority of the Turkish pulmonologists are aware of the international guideline recommendations. Despite this awareness and despite having a new national consensus report there are gaps in diagnosis and treatment of IPF. The study was carried out according to the principles of the Declaration of Helsinki. REFERENCES 1- Sgalla G, Lovene B, Calvello M, et al. Idiopathic Pulmonary Fibrosis: pathogenesis and management. Respir Res 2018;19:32. doi: /s
10 10 2- Walters PJ, Blackwell TS, Eickelberg O, et al. Time for change: is idiopathic pulmonary fibrosis still idiopathic and only fibrotic? Lancet Respir Med 2018;6: Nalysnyk L, Cid-Ruzafa J, Rotella P, et al. Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature. Eur Respir Rev 2012;21: Raghu G, Chen SY, Hou Q, et al. Incidence and prevalence of idiopathic pulmonary fibrosis in US adults years old. Eur Respir J 2016;48: Strongmen H, Kausar I, Maher TB. Incidence, prevalence and survival of patients with idiopathic pulmonary fibrosis in the UK. Adv Ther 2018;35: Musellim B, Okumus G, Uzaslan E, et al. Epidemiology and distribution of interstitial lung diseases in Turkey. Clin Respir J 2014;8: Raghu G, Collard HR, Egan JJ, et al. An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management. Am J Respir Crit Care Med 2011;183: Ergur GA, Bingöl Z, Kumbasar ÖÖ, et al. Türk Toraks Derneği idiyopatik pulmoner fibrosis tanı ve tedavi uzlaşı raporu Türk Toraks Derneği yayınları The idiopathic pulmonary fibrosis clinical research network, Raghu G, Anstrom KJ, et al. Prednisone, Azathioprine, and N-Acetylcsyteine for pulmonary fibrosis. N Engl J Med 2012;366; Noth I, Anstrım KJ, Calvert SB, et al. A placebo controlled randomized trial of warfarin in idiopathic pulmonary fibrosis. Am J Respir Crit Care Med 2012;186: Cottin V. Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: AIR survey. Eur Respir Rev 2014;23: Piotrowski WJ, Martusewicz-Boros MM, Bialas AJ, et al. Idiopathic pulmonary fibrosiscommon practice in Poland before the antifibrotic era. Adv Respir Med 2017;85: Cherrez-Ojeda I, Cottin V, Calderon JC. Management and attidudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America. BMC Pulm Med 2018;18:5. doi: /s
11 Cottin V, Cadranel J, Crestani B, et al. Management of idiopathic pulmonary fibrosis in France: A survey of 1244 pulmonologists Respir Med 2014:108; Raghu G, Remy-Jardin M, Myers JL, et al. Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 2018:198;e44-e Torrisi SE, Pavone M, Vancheri A, et al. When to start and when to stop antifibrotic therapies. Eur Respir Rev 2017:26; doi: /
12 12 Table 1: Characteristics of the physicians participating in the survey Questions Responses N % Gender Female Male Age < > Institution Title Number of IPF patients treated by a physician in one year MH: Ministry of Health Public Hospital MH Academic Hospital University Hospital Private Hospital Specialist Assistant professor Associate professor Professor < >
13 Response % 13 Figure 1: Proportion of physicians with access to radiologist and pathologist % 67% % 10% 22% 23% 0 Yes Have facility to access but not in the same hospital No Radiologist Pathologist
14 Response % 14 Figure 2: Proportion of physicians with access to multidisciplinary discussion % 38% % Always Sometimes Never
15 Response % 15 Figure 3: Average symptom duration (months) before diagnosis of IPF < >24
16 Response % 16 Figure 4: Percentage of physicians who prescribe treatment for IPF % 10% 8% 12% 10% 78% 50%
17 Response % 17 Figure 5: Percentage of physicians who prescribe antifibrotic drugs for patients with definite and probable IPF % % 10 0 Patients with definite IPF diagnosis Patients with probable IPF diagnosis As soon as I get the diagnosis I start I follow the patient for at least three months if necessary I start Firstly I start immunosuppressive therapy, if there is no response I start
18 Response % 18 Figure 6: The most common comorbidities in IPF patients GER Emphysema Pulmonary Hipertension Lung cancer Sleep apnea Cardiovascular diseases Always Sometimes Never
19 19
20 20
Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey
REVIEW IDIOPATHIC PULMONARY FIBROSIS Current approaches to the diagnosis and treatment of idiopathic pulmonary fibrosis in Europe: the AIR survey Vincent Cottin 1,2 Affiliations: 1 Hospices Civils de Lyon,
More informationERS 2016 Congress Highlights Interstitial Lung Disease (ILD)
ERS 216 Congress Highlights Interstitial Lung Disease (ILD) London, UK September 3 rd 7 th 216 The 26 th European Respiratory Society International Congress, (ERS) the largest respiratory meeting in the
More informationOFEV MEDIA BACKGROUNDER
OFEV MEDIA BACKGROUNDER 1 What is OFEV (nintedanib*)? 2 How does OFEV (nintedanib*) work? 3 Data overview 4 OFEV (nintedanib*) approval status 1 What is OFEV (nintedanib*)? OFEV (nintedanib*) is a small
More informationSummary: Key Learning Points, Clinical Strategies, and Future Directions
Summary: Key Learning Points, Clinical Strategies, and Future Directions Introduction Idiopathic pulmonary fibrosis (IPF), a peripheral lobular fibrosis of unknown cause, is a chronic, progressive lung
More informationTherapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic
Therapies for Idiopathic Pulmonary Fibrosis Pharmacologic, Non-Pharmacologic Amy Olson, MD, MSPH Associate Professor, Division of Pulmonary and Critical Care Medicine National Jewish Health, Denver, CO
More informationTriple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis
Editorial Triple kinase inhibitor with phosphodiesterase-5 inhibitor for idiopathic pulmonary fibrosis Tomoo Kishaba Department of Respiratory Medicine, Okinawa Chubu Hospital, Uruma City, Okinawa, Japan
More informationDIAGNOSTIC NOTE TEMPLATE
DIAGNOSTIC NOTE TEMPLATE SOAP NOTE TEMPLATE WHEN CONSIDERING A DIAGNOSIS OF IDIOPATHIC PULMONARY FIBROSIS (IPF) CHIEF COMPLAINT HISTORY OF PRESENT ILLNESS Consider IPF as possible diagnosis if any of the
More informationNINTEDANIB MEDIA BACKGROUNDER
NINTEDANIB MEDIA BACKGROUNDER 1. What is nintedanib? 2. How does nintedanib work? 3. Data overview 4. International treatment guidelines for IPF 1. What is nintedanib? Nintedanib (OFEV a ) is a small molecule
More informationNintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis
Nintedanib and Pirfenidone: New Medications in the Management of Idiopathic Pulmonary Fibrosis Brad Zimmermann, PharmD, MBA Pharmacy Grand Rounds May 02, 2017 Rochester, Minnesota 2017 MFMER slide-1 Objectives
More informationNew Horizons The Future of IPF and ILD
New Horizons The Future of IPF and ILD Talmadge E. King, Jr., M.D. Julius R. Krevans Distinguished Professorship in Internal Medicine Chair, Department of Medicine University of California San Francisco
More informationConnective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates
Connective Tissue Disorder- Associated Interstitial Lung Disease (CTD-ILD) and Updates Maria Elena Vega, M.D Assistant Professor of Medicine Lewis Katz School of Medicine at Temple University Nothing to
More informationExperience with the Compassionate Use Program of nintedanib for the treatment of Idiopathic Pulmonary Fibrosis in Argentina
ORIGINAL 131 RAMR 2017;2:131-135 ISSN 1852-236X Correspondence Gabriela Tabaj gabrielatabaj@gmail.com Received: 11.15.2016 Accepted: 02.03.2017 Experience with the Compassionate Use Program of nintedanib
More informationA case of a patient with IPF treated with nintedanib. Prof. Kreuter and Prof. Heussel
A case of a patient with IPF treated with nintedanib Prof. Kreuter and Prof. Heussel Case Overview This case describes the history of a patient with IPF who, at the time of diagnosis, had symptoms typical
More informationEvidence-based treatment strategies in idiopathic pulmonary fibrosis
Eur Respir Rev 2013; 22: 128, 163 168 DOI: 10.1183/09059180.00001013 CopyrightßERS 2013 REVIEW Evidence-based treatment strategies in idiopathic pulmonary fibrosis Jürgen Behr ABSTRACT: Recently updated
More informationIDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management
IDIOPATHIC PULMONARY FIBROSIS Guidelines for Diagnosis and Management An ATS Pocket Publication This publication was produced in collaboration with Boehringer Ingelheim Pharmaceuticals, Inc. GUIDELINES
More informationPNEUMOLOGIA 2018 Milano, giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE. Il futuro dell IPF: dove stiamo andando. Carlo Albera
PNEUMOLOGIA 2018 Milano, 14 16 giugno 2018 INTERSTIZIOPATIE E MALATTIE RARE Il futuro dell : dove stiamo andando Carlo Albera Università di Torino, Scuola di Medicina Dipartimento di Scienze Cliniche e
More informationChallenges in the classification of fibrotic ILD
Review SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; Suppl. 1: 4-9 Mattioli 1885 Challenges in the classification of fibrotic ILD Elisabeth Bendstrup 1, Toby M. Maher 2, Effrosyni D. Manali
More informationPatient with FVC>90% predicted. Demosthenes Bouros, Vasilios Tzilas University of Athens
Patient with FVC>90% predicted Demosthenes Bouros, Vasilios Tzilas University of Athens CASE OVERVIEW A 63-year-old, male patient with progressive exertional dyspnoea lasting for 2 years and dry cough
More informationRole of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study
36 Journal of The Association of Physicians of India Vol. 64 May 2016 Original Article Role of Pirfenidone in Idiopathic Pulmonary Fibrosis - A Longitudinal Cohort Study KP Suraj 1, Neethu K Kumar 2, E
More informationDiagnosing ILD. What is important in 2016? Chris Grainge
Diagnosing ILD What is important in 2016? Chris Grainge Senior Staff Specialist Respiratory Medicine John Hunter Hospital Conjoint A/Prof University of Newcastle Conflict of interest I have acted as a
More informationContemporary Clinical Trials Communications
Contemporary Clinical Trials Communications 3 (2016) 80e85 Contents lists available at ScienceDirect Contemporary Clinical Trials Communications journal homepage: www.elsevier.com/locate/conctc Idiopathic
More informationNeglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment
REVIEW IDIOPATHIC PULMONARY FIBROSIS Neglected evidence in idiopathic pulmonary fibrosis and the importance of early diagnosis and treatment Vincent Cottin 1,2 and Luca Richeldi 3,4 Affiliations: 1 Hospices
More informationA PARTNERSHIP PLAN FOR IDIOPATHIC PULMONARY FIBROSIS
A PARTNERSHIP PLAN FOR IDIOPATHIC PULMONARY FIBROSIS A STRATEGY FOR DEVELOPING AN IPF MANAGEMENT PLAN BASED ON REALISTIC PATIENT GOALS Indication Esbriet (pirfenidone) is indicated for the treatment of
More informationInternational consensus statement on idiopathic pulmonary fibrosis
Eur Respir J 2001; 17: 163 167 Printed in UK all rights reserved Copyright #ERS Journals Ltd 2001 European Respiratory Journal ISSN 0903-1936 PERSPECTIVE International consensus statement on idiopathic
More informationLong-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective analysis
Original article: Clinical research SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2016; 33; 242-246 Mattioli 1885 Long-term efficacy of macrolide treatment in idiopathic pulmonary fibrosis: a retrospective
More informationChallenges in Pulmonary and Critical Care: 2018
Challenges in Pulmonary and Critical Care: 2018 Interstitial Lung Disease: Evolving Our Understanding of a Deadly Disease 1 Faculty Kevin Flaherty, MD, MS Professor in Pulmonary and Critical Care Medicine
More informationHypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas
Hypersensitivity Pneumonitis Common Diagnostic and Treatment Dilemmas Rishi Raj MD Director, Interstitial Lung Diseases Program Clinical Professor of Pulmonary and Critical Care Medicine Stanford University
More informationManagement and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
Cherrez-Ojeda et al. BMC Pulmonary Medicine (2018) 18:5 DOI 10.1186/s12890-017-0569-1 RESEARCH ARTICLE Management and attitudes about IPF (Idiopathic Pulmonary Fibrosis) among physicians from Latin America
More informationRandomized Trial of Acetylcysteine in Idiopathic Pulmonary Fibrosis
original article Randomized Trial of in Idiopathic Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* ABSTRACT Background has been suggested as a beneficial treatment for idiopathic
More informationCurrent diagnostic recommendations for ILD: The multidisciplinary meeting TSANZSRS ASM
Medicine, Nursing and Health Sciences Current diagnostic recommendations for ILD: The multidisciplinary meeting Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Idiopathic Pulmonary Fibrosis Page 1 of 10 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Idiopathic Pulmonary Fibrosis (Esbriet /pirfenidone, Ofev /nintedanib)
More informationDisclosures. Traditional Paradigm. Overview 4/17/2010. I have relationships with the following organizations and companies:
Disclosures Pharmacological Therapy for ILD What to Use and How to Use It Harold R Collard MD Interstitial Lung Disease Program University of California San Francisco (UCSF) I have relationships with the
More informationDifferential diagnosis
Differential diagnosis Idiopathic pulmonary fibrosis (IPF) is part of a large family of idiopathic interstitial pneumonias (IIP), one of four subgroups of interstitial lung disease (ILD). Differential
More informationCurrent Management of IPF and. Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine
Current Management of IPF and fibrosing ILDs Dr R Lakshmi Narasimhan Dept of Pulmonary Medicine Introduction Idiopathic pulmonary fibrosis clinical course is variable and long term survival is poor Therapy
More informationReview of idiopathic pulmonary fibrosis diagnosis and management recommendations in Europe
Review SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2013; 30; 249-261 Mattioli 1885 Review of idiopathic pulmonary fibrosis diagnosis and management recommendations in Europe A. Xaubet 1, J. Behr 2,
More informationOfficial ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis
Official ATS/ERS/JRS/ALAT Clinical Practice Guidelines: Treatment of Idiopathic Pulmonary Fibrosis An Update of the 2011 Clinical Practice Guideline Online Supplement Ganesh Raghu, Bram Rochwerg, Yuan
More informationINTERSTITIAL LUNG DISEASE. Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018
INTERSTITIAL LUNG DISEASE Radhika Reddy MD Pulmonary/Critical Care Long Beach VA Medical Center January 5, 2018 Interstitial Lung Disease Interstitial Lung Disease Prevalence by Diagnosis: Idiopathic Interstitial
More informationCase Presentations in ILD. Harold R. Collard, MD Department of Medicine University of California San Francisco
Case Presentations in ILD Harold R. Collard, MD Department of Medicine University of California San Francisco Outline Overview of diagnosis in ILD Definition/Classification High-resolution CT scan Multidisciplinary
More informationDiagnostic challenges in IPF
Medicine, Nursing and Health Sciences Diagnostic challenges in IPF Dr Ian Glaspole Central and Eastern Clinical School, Alfred Hospital and Monash University March 2015 Disclosures Consultancy fees from
More informationOutline Definition of Terms: Lexicon. Traction Bronchiectasis
HRCT OF IDIOPATHIC INTERSTITIAL PNEUMONIAS Disclosures Genentech, Inc. Speakers Bureau Tadashi Allen, MD University of Minnesota Assistant Professor Diagnostic Radiology 10/29/2016 Outline Definition of
More informationGuidelines for Diagnosis and Treatment of IPF
Guidelines for Diagnosis and Treatment of IPF Katerina Antoniou, MD, PhD Lecturer in Thoracic Medicine ERS ILD Group Secretary Medical School, University of Crete Classification of Interstitial Lung Disease
More informationNew Drug Evaluation: Pirfenidone capsules, oral
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35 Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationPresente e futuro della terapia della fibrosi polmonare idiopatica
Presente e futuro della terapia della fibrosi polmonare idiopatica Antonella Caminati U.O. di Pneumologia e Terapia Semi Intensiva Servizio di Fisiopatologia Respiratoria ed Emodinamica Polmonare Osp.
More informationAdherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey
ORIGINAL ARTICLE INTERSTITIAL LUNG DISEASE Adherence to guidelines in idiopathic pulmonary fibrosis: a follow-up national survey Vincent Cottin 1, Emmanuel Bergot 2, Arnaud Bourdin 3, Jacques Cadranel
More informationProgress in Idiopathic Pulmonary Fibrosis
Progress in Idiopathic Pulmonary Fibrosis David A. Lynch, MB Disclosures Progress in Idiopathic Pulmonary Fibrosis David A Lynch, MB Consultant: t Research support: Perceptive Imaging Boehringer Ingelheim
More informationChallenges in Pulmonary and Critical Care 2017
Challenges in Pulmonary and Critical Care 2017 Idiopathic Pulmonary Fibrosis: New Advances in Therapy Outcome Report: Boehringer Ingelheim Grant # ME201722329 February 2, 2018 Level 1 (Participation) Practice
More informationInvestor Update. Services. Investor Relations team Send . Basel, 24 May Subscribe to Roche news
Investor Update Basel, 24 May 2017 New data at ATS add to the body of evidence for Roche s Esbriet (pirfenidone) in idiopathic pulmonary fibrosis (IPF) In new post hoc analyses of phase III data, Esbriet
More informationWhen to start and when to stop antifibrotic therapies
REVIEW ANTIFIBROTIC THERAPIES When to start and when to stop antifibrotic therapies Sebastiano Emanuele Torrisi, Mauro Pavone, Ada Vancheri and Carlo Vancheri Affiliation: Regional Referral Centre for
More informationThe radiological differential diagnosis of the UIP pattern
5th International Conference on Idiopathic Pulmonary Fibrosis, Modena, 2015, June 12th The radiological differential diagnosis of the UIP pattern Simon Walsh King s College Hospital Foundation Trust London,
More informationDiffuse Interstitial Lung Diseases: Is There Really Anything New?
: Is There Really Anything New? Sujal R. Desai, MBBS, MD ESTI SPEAKER SUNDAY Society of Thoracic Radiology San Antonio, Texas March 2014 Diffuse Interstitial Lung Disease The State of Play DILDs Is There
More informationTODAY IS THE DAY I STAND UP TO IPF. fightipf.ca. Talking to your doctor about IPF and your options
fightipf.ca SUPPORTING PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS TODAY IS THE DAY I STAND UP TO IPF Talking to your doctor about IPF and your options WHAT IT MEANS TO HAVE IPF Idiopathic Pulmonary Fibrosis,
More informationConflicts of Interest. Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck
Conflicts of Interest Advisory Board: Boehringer-Ingleheim, Genentech/Roche DSMB: Bristol-Myers Squibb, Fibrogen Clinical Endpoint Committee; Merck The Idiopathic Interstitial Pneumonias Idiopathic pulmonary
More informationControversies in Clinical Trials. Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF)
Controversies in Clinical Trials Pirfenidone for Idiopathic Pulmonary Fibrosis (IPF) Controversies to be highlighted by IPF Post-hoc analyses Story Primary end point selection Changing prespecified endpoints
More informationUsual Interstitial pneumonia and Nonspecific Interstitial Pneumonia. Nitra and the Gangs.
Usual Interstitial pneumonia and Nonspecific Interstitial Pneumonia Nitra and the Gangs. บทน ำและบทท ๓, ๑๐, ๑๒, ๑๓, ๑๔, ๑๕, ๑๗ Usual Interstitial Pneumonia (UIP) Most common & basic pathologic pattern
More informationRadiologic pathologic discordance in biopsy-proven usual interstitial pneumonia
ERJ Express. Published on February 25, 2016 as doi: 10.1183/13993003.01680-2015 ORIGINAL ARTICLE IN PRESS CORRECTED PROOF Radiologic pathologic discordance in biopsy-proven usual interstitial pneumonia
More informationClinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis
Original Article Clinico-radiological features and efficacy of anti-fibrotic agents in atypical idiopathic pulmonary fibrosis Keishi Sugino 1, Hiroshige Shimizu 1, Yasuhiko Nakamura 1, Takuma Isshiki 1,
More information5/9/2015. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. No, I am not a pulmonologist! Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective No, I am not a pulmonologist! Radiology Pathology Clinical 1 Everyone needs a CT Confidence in diagnosis Definitive HRCT +
More informationManagement of Co morbidities in Idiopathic Pulmonary Fibrosis. Disclosures
Management of Co morbidities in Idiopathic Pulmonary Fibrosis Joyce S. Lee, MD MAS Director, Interstitial Lung Disease Clinic University of California, San Francisco Disclosures Intermune, advisory board
More informationPrednisone, Azathioprine, and N-Acetylcysteine for Pulmonary Fibrosis
T h e n e w e ngl a nd j o u r na l o f m e dic i n e original article,, and N-Acetylcysteine for Pulmonary Fibrosis The Idiopathic Pulmonary Fibrosis Clinical Research Network* A bs tr ac t The members
More informationINTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF)
INTERSTITIAL LUNG DISEASES: FOCUS ON IDIOPATHIC PULMONARY FIBROSIS (IPF) Marilyn K. Glassberg Csete, M.D. Professor of Medicine, Surgery, and Pediatrics Director, Interstitial and Rare Lung Disease Program
More informationIPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK?
IPF AND OTHER FIBROSING LUNG DISEASE: WHAT DRUGS MIGHT WORK AND ON WHOM DO THEY W ORK? KEVIN K. BROWN, MD PROFESSOR AND VICE CHAIRMAN, DEPARTMENT OF MEDICINE NATIONAL JEWISH HEALTH DENVER, CO Kevin K.
More information4/17/2010 C ini n ca c l a Ev E a v l a ua u t a ion o n of o ILD U dat a e t e i n I LDs
Update in ILDs Diagnosis 101: Clinical Evaluation April 17, 2010 Jay H. Ryu, MD Mayo Clinic, Rochester MN Clinical Evaluation of ILD Outline General aspects of ILDs Classification of ILDs Clinical evaluation
More informationPulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment
Prague, June 2014 Pulmonary manifestations of CTDs Diagnosis, differential diagnosis and treatment Katerina M. Antoniou, MD, PhD As. Professor in Thoracic Medicine ERS ILD Group Secretary Medical School,
More informationAssociation between idiopathic pulmonary fibrosis and gastroesophageal reflux disease: a meta-analysis
Association between idiopathic pulmonary fibrosis and gastroesophageal reflux disease: a meta-analysis David Bédard Méthot, MD, Internal Medicine Resident Evelyne Leblanc, MD, Internal Medicine Resident
More informationRecommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society
Expert Consensus Recommendations for the management of idiopathic pulmonary fibrosis in South Africa: a position statement of the South African Thoracic Society Coenraad F. N. Koegelenberg 1, Gillian M.
More informationUpdate on Therapies for Idiopathic Pulmonary Fibrosis. Outline
Update on Therapies for Idiopathic Pulmonary Fibrosis Paul Wolters Associate Professor University of California, San Francisco Outline Classification of Interstitial lung disease Clinical classification
More informationIdiopathic pulmonary fibrosis (IPF) is a complex, progressive
Strategies to Manage Costs in Idiopathic Pulmonary Fibrosis Gary M. Owens, MD Idiopathic pulmonary fibrosis (IPF) is a complex, progressive disease, challenging to diagnose, due to the need to exclude
More informationInterstitial Lung Disease
Interstitial Lung Disease Interstitial lung disease (ILD) is a broad category of lung diseases that includes more than 130 disorders which are characterized by scarring (i.e. fibrosis ) and/or inflammation
More informationImaging: how to recognise idiopathic pulmonary fibrosis
REVIEW IDIOPATHIC PULMONARY FIBROSIS Imaging: how to recognise idiopathic pulmonary fibrosis Anand Devaraj Affiliations: Dept of Radiology, St George s Hospital, London, UK. Correspondence: Anand Devaraj,
More informationPirfenidone improves survival in IPF: results from a real-life study
Margaritopoulos et al. BMC Pulmonary Medicine (2018) 18:177 https://doi.org/10.1186/s12890-018-0736-z RESEARCH ARTICLE Pirfenidone improves survival in IPF: results from a real-life study George A. Margaritopoulos
More informationInterstitial Lung Diseases: Respiratory Review of 2013
REVIEW http://dx.doi.org/10.4046/trd.2013.75.2.47 ISSN: 1738-3536(Print)/2005-6184(Online) Tuberc Respir Dis 2013;75:47-51 Interstitial Lung Diseases: Respiratory Review of 2013 Yong Hyun Kim, M.D. and
More informationNew Therapies and Trials in IPF
Conflict of interest disclosure I have the following real or perceived conflicts of interest that relate to this presentation: New Therapies and Trials in IPF Talmadge E. King, Jr., M.D. Julius R. Krevans
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Idiopathic Pulmonary Fibrosis Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective
More informationBaseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry
ORIGINAL ARTICLE INTERSTITIAL LUNG DISEASES Baseline characteristics of idiopathic pulmonary fibrosis: analysis from the Australian Idiopathic Pulmonary Fibrosis Registry Helen E. Jo 1,2, Ian Glaspole
More informationInterstitial Lung Disease (ILD)
Interstitial Lung Disease (ILD) ILD comprises more than 130 distinct disorders Characterized by cellular proliferation, cellular infiltration, and/or fibrosis of the lung parenchyma not due to infection
More informationLimitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis Limitations of Corticosteroids and Cytotoxic Agents in Treating Idiopathic Pulmonary Fibrosis JMAJ 46(11): 475 482, 2003 Kingo CHIDA Associate Professor, Second Division,
More informationIPF: from clinical trials to real life
IPF: from clinical trials to real life Sergio Harari U.O. di Pneumologia e UTIR Servizio di Emodinamica e Fisiopatologia Respiratoria Ospedale San Giuseppe MultiMedica - Milano Conflict of interests disclosures
More informationTBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than
TBLB is not recommended as the initial biopsy option in cases of suspected IPF and is unreliable in the diagnosis of rare lung disease (other than PAP) BAL is not required as a diagnostic tool in patients
More informationPathologic Assessment of Interstitial Lung Disease
Pathologic Assessment of Interstitial Lung Disease Dry and itchy? It could be eczema or fungal infection. We don t need to worry, the drugs aren t that dangerous. Kirk D. Jones, MD UCSF Dept. of Pathology
More informationIntractable & Rare Diseases Research. 2017; 6(2):
Review Intractable & Rare Diseases Research. 2017; 6(2):80-86. 80 DOI: 10.5582/irdr.2017.01014 Idiopathic pulmonary fibrosis in East Asian Changbo Sun, Yanbin Sun, Hui Shen, Chunlu Yang, Shun Xu* Department
More informationDo randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary fibrosis
Page 1 of 6 AJRCCM Articles in Press. Published on 25-August-2017 as 10.1164/rccm.201708-1666ED Do randomized clinical trials always provide certain results? The case of tralokinumab in idiopathic pulmonary
More informationIdiopathic Pulmonary Fibrosis: A Study of 46 Patients from Western India: Clinical Presentations and Survival
Turk Thorac J 205; 6:4-20 DOI: 0.552/ttd.205.4584 ORIGINAL INVESTIGATION Idiopathic Pulmonary Fibrosis: A Study of 46 Patients from Western India: Clinical Presentations and Survival Subramanian Natarajan,
More informationIncidence and prevalence of idiopathic pulmonary fibrosis: review of the literature
Eur Respir Rev 12; 21: 126, 355 361 DOI: 1.1183/95918.2512 CopyrightßERS 12 REVIEW Incidence and prevalence of idiopathic pulmonary fibrosis: review of the literature Luba Nalysnyk*, Javier Cid-Ruzafa
More informationUIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION!
UIP OR NOT UIP PATTERN: THAT IS NOT THE ONLY QUESTION! STÉPHANE JOUNEAU 11 JULY 2014 Respiratory Medicine Department, Pontchaillou Hospital, Rennes, France CASE OVERVIEW This case highlights how a usual
More informationMalattie respiratorie: terapia e aderenza terapeutica nel paziente anziano
La Cronicità: Dall Ospedale al territorio, una realtà in evoluzione Malattie respiratorie: terapia e aderenza terapeutica nel paziente anziano Dr. Sergio Harari U.O. di Pneumologia Ospedale San Giuseppe
More informationEvaluating New Treatment Options
Evaluating New Treatment Options Steven D. Nathan, MD Clinical Practice Guideline Changes 211 ATS/ERS/JRS/ALAT Recommendations Treatment of IPF combines nonpharmacologic and pharmacologic strategies, and
More informationNon-neoplastic Lung Disease II
Pathobasic Non-neoplastic Lung Disease II Spasenija Savic Prince Pathology Program Systematic approach to surgical lung biopsies with ILD Examples (chronic ILD): Idiopathic interstitial pneumonias: UIP,
More informationAn earlier and more confident diagnosis of idiopathic pulmonary fibrosis
Eur Respir Rev 2012; 21: 124, 141 146 DOI: 10.1183/09059180.00000812 CopyrightßERS 2012 REVIEW: IPF An earlier and more confident diagnosis of idiopathic pulmonary fibrosis Roland M. du Bois ABSTRACT:
More informationIdiopathic pulmonary fibrosis (IPF), previously known as
Overview of Idiopathic Pulmonary Fibrosis (IPF) and Evidence-Based Guidelines Roozbeh Sharif, MD, MEd, MSc Idiopathic pulmonary fibrosis (IPF), previously known as cryptogenic fibrosing alveolitis, is
More informationLaparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre
ORIGINAL ARTICLE INTERSTITIAL LUNG DISEASES Laparoscopic anti-reflux surgery for idiopathic pulmonary fibrosis at a single centre Ganesh Raghu 1, Ellen Morrow 2, Bridget F. Collins 1, Lawrence A.T. Ho
More informationDisclosures. Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting. Relevant financial relationships: None. Off-label usage: None
Fibrotic lung diseases: Basic Principles, Common Problems, and Reporting Brandon T. Larsen, MD, PhD Senior Associate Consultant Department of Laboratory Medicine and Pathology Mayo Clinic Arizona Arizona
More informationIdiopathic pulmonary fibrosis
Pharmacologic Treatments for Idiopathic Pulmonary Fibrosis This chronic disease has historically lacked an effective treatment option, but the FDA recently approved two: pirfenidone and nintedanib. This
More informationPerspectives ILD Diagnosis and Treatment in 5-10 years
Perspectives ILD Diagnosis and Treatment in 5-10 years Brett Ley, MD Department of Medicine The (Near) Future of ILD Diagnosis and Treatment 1. Combination therapy for Idiopathic Pulmonary Fibrosis 2.
More informationUntil approximately 40 yrs ago, clinical. Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis REVIEW: IPF
Eur Respir Rev 2012; 21: 124, 147 151 DOI: 10.1183/09059180.00000912 CopyrightßERS 2012 REVIEW: IPF Assessing the treatment effect from multiple trials in idiopathic pulmonary fibrosis Luca Richeldi ABSTRACT:
More informationManuscript Draft. Title: What if we made stratified medicine work for patients?
Respiratory Medicine Elsevier Editorial System(tm) for The Lancet Manuscript Draft Manuscript Number: Title: What if we made stratified medicine work for patients? Article Type: Comment Keywords: stratified
More informationPirfenidone: an update on clinical trial data and insights from everyday practice
REVIEW IDIOPATHIC PULMONARY FIBROSIS Pirfenidone: an update on clinical trial data and insights from everyday practice Michael Kreuter 1,2 Affiliations: 1 Dept of Pneumology and Respiratory Critical Care
More information11/10/2014. Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective. Radiology
Multi-disciplinary Approach to Diffuse Lung Disease: The Imager s Perspective Radiology Pathology Clinical 1 Role of HRCT Diagnosis Fibrosis vs. inflammation Next step in management Response to treatment
More informationNOTICE OF SUBSTANTIAL AMENDMENT
NOTICE OF SUBSTANTIAL AMENDMENT For use in the case of all research other than clinical trials of investigational medicinal products (CTIMPs). For substantial amendments to CTIMPs, please use the EU-approved
More informationTODAY IS THE DAY I STAND UP TO IPF. fightipf.co.uk
fightipf.co.uk SUPPORTING IPF AWARENESS TODAY IS THE DAY I STAND UP TO IPF For people diagnosed with Idiopathic Pulmonary Fibrosis: A guide to help you discuss your condition and management options with
More informationDisclosures. IPF Medications: Practical Experience. Prednisone, Azathioprine, N acyetylcysteine. Case 1. Brett Ley, MD, MAS Assistant Professor, UCSF
IPF Medications: Practical Experience Disclosures Received speakers bureau honorarium from Roche/Genentech (makers of pirfenidone). Brett Ley, MD, MAS Assistant Professor, UCSF 67 y/o man 1 year cough
More information